• Neuralink's Blindsight implant aims to restore vision by stimulating the visual cortex directly, bypassing the eyes and optic nerve entirely.
• The device received FDA Breakthrough Device Designation in September 2024 and has shown promising results in non-human primate trials.
• First human implants are expected in 2026, with initial resolution being low but improving as hardware generations advance.

What Is Neuralink's Blindsight?

Blindsight is Neuralink's second major product line, distinct from the Telepathy device currently implanted in PRIME and VOICE trial patients. Where Telepathy reads signals from the motor and speech cortices to translate intent into action, Blindsight works in the opposite direction: it writes information into the brain. Specifically, it stimulates neurons in the visual cortex to produce the sensation of sight.

The goal is ambitious. Neuralink has stated that Blindsight could eventually restore vision to people who have lost their sight through injury or disease — and crucially, even to those who were born blind, provided their visual cortex developed normally.

How Blindsight Differs from Existing Vision Implants

Other vision-restoration devices, such as the Argus II retinal implant (discontinued in 2019) or newer optical prosthetics from companies like Science Corporation, work by replacing damaged cells at the eye. That approach only helps patients whose optic nerve and downstream visual processing pathways are still intact.

Blindsight bypasses the entire visual pathway. By directly stimulating the visual cortex at the back of the brain, it should work regardless of whether the patient's eyes, retina, or optic nerve function. Cortical visual prosthetics have existed in experimental form for decades, but Neuralink is the first to pair the approach with its thin-thread, high-channel-count N1 platform — which could deliver far higher resolution than previous attempts.

The Science: Writing Signals Into the Visual Cortex

The visual cortex is organized retinotopically, meaning that neurons in a specific cortical location correspond to a specific spot in the visual field. When a neuron is stimulated with a small electrical pulse, the subject perceives a bright dot — called a phosphene — at the corresponding location in their field of view.

By stimulating many neurons in a coordinated pattern, the brain can be made to perceive rudimentary shapes, letters, and eventually, images. The more electrodes delivering the more precise stimulation, the higher the effective resolution of the perceived image. Neuralink's flexible threads, each carrying multiple electrodes, are well suited to this task because they can deliver finely-targeted stimulation across a wide cortical area with minimal tissue damage.

Animal Trial Results So Far

Neuralink has tested Blindsight extensively in non-human primates. In March 2024, Elon Musk confirmed the device was already functional in monkeys, with a blind monkey reportedly navigating a small environment using the implant. Monkeys have been a critical test bed because their visual cortex architecture closely mirrors that of humans, making their outcomes highly predictive of what human trials should show.

You can read about Neuralink's broader animal trial record in this article. The progression from primates to humans mirrors the cautious path Neuralink took with the PRIME study.

Regulatory Status: FDA Breakthrough Device Designation

In September 2024, Blindsight received Breakthrough Device Designation from the FDA. This status doesn't approve the device for use — rather, it accelerates the regulatory review process for technologies that treat irreversibly debilitating conditions and show substantial clinical advantage over existing options. It allows for more frequent FDA interaction, prioritized review, and expedited approval once trial data supports it.

Telepathy received similar designation before the PRIME trial began, and speech-restoration technology received the same designation in mid-2025 ahead of the VOICE trial. That precedent suggests Blindsight will follow a similar path — an early feasibility study with a handful of participants, followed by broader clinical trials if initial data is positive.

Who Will Qualify for the First Human Trials

Neuralink has not yet published official inclusion criteria for Blindsight on ClinicalTrials.gov as of early 2026. Based on patterns from PRIME and VOICE, the first participants will likely fit this profile:

• Adults, likely aged 22–75.
• Profound vision loss — total or near-total blindness, whether from injury, disease, or congenital causes.
• An intact visual cortex, confirmed through MRI imaging.
• A stable caregiver and the ability to participate in extended follow-up.
• Absence of major psychiatric conditions or surgical risk factors (standard Neuralink exclusions).

The first trial site will most likely be one of Neuralink's existing US partners, though international expansion — already underway for PRIME through CAN-PRIME in Canada and UK efforts — could follow quickly if safety data supports it.

What First Users Should Expect

Elon Musk has been characteristically candid about the limits of first-generation Blindsight. Early users will likely experience very low-resolution vision — sometimes described as "early Nintendo" or "Atari-level graphics" — consisting of a grid of bright and dark dots rather than photographic imagery. The brain, however, is remarkably adaptive. Over time, users often learn to interpret this low-resolution input as meaningful shapes, motion, and eventually navigable imagery.

Successive device generations, with denser thread counts and better stimulation algorithms, are expected to improve resolution substantially. Musk has suggested that, with enough electrodes, Blindsight could eventually exceed natural human vision — potentially seeing in non-visible spectra such as infrared. Whether that ambitious vision arrives in five years or twenty depends on engineering progress and regulatory pace.

Timeline and What to Watch For

Based on public statements and comparison with PRIME and VOICE, the most plausible Blindsight timeline looks like this:

• 2026: First human Blindsight implants, likely in a formal early feasibility study.
• 2026–2027: Initial outcomes data on safety, device-related adverse events, and functional vision metrics.
• 2028 and beyond: Larger pivotal trials if early feasibility data holds up.

Key signals to watch for: an FDA Investigational Device Exemption (IDE) announcement, a ClinicalTrials.gov listing for the study, and updates from Neuralink's semi-annual Show and Tell events.

Summary

Neuralink's Blindsight is a visual cortex implant designed to restore vision by directly stimulating the brain, bypassing the eyes and optic nerve entirely. It received FDA Breakthrough Device Designation in September 2024 and has been tested successfully in monkeys.

The first human implants are expected in 2026. Early users should expect low-resolution, pixelated vision that gradually improves as hardware advances and the brain adapts. Blindsight represents Neuralink's leap from reading the brain (Telepathy, VOICE) to writing directly to it — a technical jump with far-reaching implications for medicine and, eventually, human sensory augmentation.